Cabazitaxel (after Docetaxel) - Advanced Prostate...

Advanced Prostate Cancer

20,967 members26,123 posts

Cabazitaxel (after Docetaxel)

pjoshea13 profile image
2 Replies

New study (below) found that lower hemoglobin was the only prognostic factor for shorter survival.

-Patrick

ncbi.nlm.nih.gov/pubmed/296...

Can Urol Assoc J. 2018 Apr 6. doi: 10.5489/cuaj.5108. [Epub ahead of print]

Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Yokom DW1, Stewart J2, Alimohamed NS3, Winquist E4, Berry S5, Hubay S6, Lattouf JB7, Leonard H8, Girolametto C6, Saad F9, Sridhar SS1.

Author information

Abstract

INTRODUCTION:

Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel.

METHODS:

A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed. Clinical factors were analyzed by univariable and multivariable Cox proportional hazards and logistic regression analysis to identify independent predictors of prognosis and response.

RESULTS:

Forty-five patients from five centres in Canada were included in this study. On multivariable analysis, lower hemoglobin was associated with shorter survival. No other factors were independently associated with survival, prostate-specific antigen (PSA) response or primary PSA progression.

CONCLUSIONS:

Clinical factors predicting survival or treatment response were not identified for men with castration-resistant prostate cancer receiving cabazitaxel. Larger studies may be necessary to identify clinical factors and biomarkers that identify whether patients should or should not receive cabazitaxel.

PMID: 29629866 DOI: 10.5489/cuaj.5108

Written by
pjoshea13 profile image
pjoshea13
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Daddysdaughter profile image
Daddysdaughter

My father had a drop in HBG but he is no longer in chemo. 😔

It would suck to do chemo for no reasonable results or for no reason at all.

You may also like...

Can I try A rechallenge with Xtandi after using docetaxel and cabazitaxel?

failed docetaxel and now cabazitaxel/carboplatin. Planning on xofigo next but my hemoglobin has...

Docetaxel vs. Cabazitaxel--effectiveness?

PSA is still rising, even after docetaxel. MO wants him to try cabazitaxel next. My question is, is...

Abiraterone after Docetaxel for mCSPC?

high burden metastatic castrate sensitive prostate CA (mCSPC), following docetaxel. What study is...

constipation after cabazitaxel

Lu 177 PSMA vs Cabazitaxel (Jevtana) in patients with mCRPC previously treated with Docetaxel and with a progressing PSA with values >/=20.

cular-therapies-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc